Diabetic Kidney Disease: Layer Protection and Recheck the Diagnosis

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Track kidney function, potassium, volume status, adverse effects, and patient priorities. An early physiological change may differ from progressive kidney injury.

Which kidney-protective treatments fit this patient?. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Which kidney-protective treatments fit this patient?. eGFR + urine albumin — Stage risk; assess SGLT2 eligibility; Blood pressure + albumin — Consider ACE inhibitor OR ARB when indicated; Potassium + comorbidity — Assess finerenone and other therapy eligibility. Choose treatments by their indication and safety profile; schedule follow-up laboratory checks. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Multiple injury pathways

Hyperglycemia, hemodynamic stress, inflammation, and vascular disease contribute to diabetic kidney disease. Albuminuria and filtration provide complementary risk information.

Check for another disease

Abrupt decline, active sediment, unusual protein patterns, or discordant clinical features warrant reconsideration rather than automatic attribution to diabetes.

Assess the whole risk profile

Review blood pressure, glycemia, albuminuria, cardiovascular disease, potassium, medication tolerance, and access to care.

Layer by indication

For type 2 diabetes with CKD, an SGLT2 inhibitor is recommended when eGFR is ≥20 mL/min/1.73 m². Use ACEi/ARB for indicated albuminuric disease and consider finerenone for eligible patients with persistent albuminuria and acceptable potassium. A GLP-1 receptor agonist may address additional glycemic and cardiovascular needs.

Keep metformin and organ protection distinct

Metformin eligibility changes as filtration declines: KDIGO recommends it for type 2 diabetes with eGFR ≥30 mL/min/1.73 m², with dose adjustment below 45. Stop below 30 and reassess during acute illness. An SGLT2 inhibitor may still offer organ benefit when its glucose-lowering effect is smaller.

Schedule checks after each layer

Check BP, creatinine, and potassium within 2–4 weeks after starting or increasing ACEi/ARB. For finerenone, plan potassium reassessment at about 4 weeks. Review volume symptoms after SGLT2 initiation. Investigate substantial or progressive deterioration rather than treating every early eGFR dip as toxicity.

Supporting evidence

Continue learning